国元证券股份有限公司 关于安徽山河药用辅料股份有限公司 2025 年持续督导培训情况的报告 1 国元证券股份有限公司（以下简称"国元证券"）作为安徽山河药用辅料股 份有限公司（以下简称"山河药辅"或"公司"）向不特定对象发行可转换公司 债券并在创业板上市的持续督导保荐机构，根据《证券发行上市保荐业务管理办 法》《深圳证券交易所上市公司自律监管指引第13号——保荐业务》《深圳证券 交易所上市公司自律监管指引第2号——创业板上市公司规范运作》等相关规定， 保荐代表人于2025年12月19日对山河药辅的董事、监事、高级管理人员、中层以 上管理人员及控股股东和实际控制人等相关人员等进行了培训，现将本次培训情 况汇报如下： 一、培训内容 国元证券向本次培训的对象提供了书面培训资料，本次培训重点结合《证 券发行上市保荐业务管理办法》《深圳证券交易所上市公司自律监管指引第 13 号——保荐业务》以及《深圳证券交易所上市公司自律监管指引第 2 号——创 业板上市公司规范运作》等法律法规和规定，介绍了募集资金使用、同业竞争 承诺、关联交易、信息披露、窗口期交易、短线交易以及内幕信息及内幕交易 等方面的内容。 二、培训人员 根据 ...

Group 1 - The core viewpoint of the article indicates that the company, Shanhe Pharmaceutical Auxiliary, has a strong order volume for its main products, such as microcrystalline cellulose, in the fourth quarter, with stable prices and good operational performance [1] - The company reported that the losses in the fourth quarter of the previous year were due to goodwill impairment losses, which will not occur this year [1]

Group 1 - The core viewpoint of the article is that the company, Shanhe Pharmaceutical Auxiliary, has a strong order volume for its main products, such as microcrystalline cellulose, in the fourth quarter, with stable prices and good operational performance [1] - The company reported that the losses in the fourth quarter of the previous year were due to goodwill impairment losses, which will not occur this year [1]

Group 1 - The company reported that it has sufficient orders for its main product, microcrystalline cellulose, in the fourth quarter, and prices remain stable, indicating a good production and operational status [1] - The loss experienced in the fourth quarter of the previous year was due to goodwill impairment losses, which will not occur this year [1]

Market Overview - The chemical pharmaceutical sector experienced a decline of 0.23% on November 20, with Minsheng Health leading the drop [1] - The Shanghai Composite Index closed at 3931.05, down 0.4%, while the Shenzhen Component Index closed at 12980.82, down 0.76% [1] Stock Performance - Notable gainers in the chemical pharmaceutical sector included: - Hainan Haiyao (000566) with a closing price of 7.92, up 10.00% and a trading volume of 2.1875 million shares, totaling 1.634 billion yuan [1] - Kangyi Pharmaceutical (300086) closed at 12.15, up 8.97% with a trading volume of 1.4039 million shares, totaling 1.656 billion yuan [1] - Other significant gainers included Bibete (688759), Yuekang Pharmaceutical (688658), and Qianyan Bio (688221) with increases ranging from 5.43% to 7.73% [1] - Conversely, the following stocks faced declines: - Minsheng Health (301507) closed at 16.69, down 6.18% with a trading volume of 273,400 shares, totaling 463 million yuan [2] - Shanhua Pharmaceutical (300452) and Hasa Lian (002900) also saw declines of 4.45% and 4.12% respectively [2] Capital Flow - The chemical pharmaceutical sector saw a net outflow of 1.233 billion yuan from institutional investors, while retail investors contributed a net inflow of 964 million yuan [2] - Notable capital flows included: - Hainan Haiyao (000566) had a net inflow of 25.3 million yuan from institutional investors, but a net outflow of 101 million yuan from retail investors [3] - Kangyi Pharmaceutical (300086) experienced a net inflow of 56.4 million yuan from institutional investors, while retail investors saw a net outflow of 67.9 million yuan [3]

Core Viewpoint - The A-share market shows a slight decline with the Shanghai Composite Index closing at 3938.29 points, below the five-day moving average, indicating a minor negative sentiment in the market [1] Market Performance - The total trading volume of A-shares reached 1,115.728 billion yuan today [1] - The Shanghai Composite Index experienced a change of -0.04% [1] Stocks Breaking the Five-Day Moving Average - A total of 188 A-shares have surpassed the five-day moving average today [1] - Notable stocks with significant deviation rates include: - Lian Te Technology (301205) with a deviation rate of 11.68% and a daily increase of 15.88% [1] - Hengguang Co., Ltd. (301118) with a deviation rate of 11.40% and a daily increase of 19.98% [1] - Taiyong Changzheng (002927) with a deviation rate of 7.85% and a daily increase of 10.00% [1] Stocks with Smaller Deviation Rates - Stocks with smaller deviation rates that have just crossed the five-day moving average include: - Aerospace Rainbow (not specified) with a small deviation rate [1] - Gongchuang Lawn (not specified) with a small deviation rate [1] - Shoulu Hotel (not specified) with a small deviation rate [1]

Core Viewpoint - The company announced the election of its actual controller and major shareholder, Ms. Wu Changhong, as the chairman of the sixth board of directors [1] Company Summary - The board of directors of the company has approved the election of Ms. Wu Changhong as the chairman [1]

Core Viewpoint - The company has elected Wu Changhong, the actual controller and major shareholder, as the chairman of the sixth board of directors, and appointed Song Daocai as the legal representative of the company [1] Group 1 - The board of directors approved the election of Wu Changhong as the chairman, with the term starting from the date of board approval until the end of the sixth board's term [1] - The company’s articles of association state that the chairman or general manager serves as the legal representative of the company [1] - Song Daocai has been elected as the legal representative, and the management team is authorized to handle the necessary business registration changes [1]

公司董事会同意选举公司实际控制人、控股股东吴长虹女士为第 六届董事会董事长，任期自董事会审议通过之日起至第六届董事会任 期届满之日止。 关于选举董事长、变更法定代表人及调整董事会专门委 员会委员的公告 本公司及董事会全体成员保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏。 安徽山河药用辅料股份有限公司（以下简称"公司"）于 2025 年 11 月 6 日召开 2025 年第二次临时股东会，审议通过了《关于补 选公司第六届董事会非独立董事的议案》，同意补选吴长虹女士为公 司第六届董事会非独立董事，任期自公司股东会审议通过之日起至第 六届董事会任期届满之日止。2025 年 11 月 7 日上午，公司召开第六 届董事会第九次会议，审议通过了《关于选举公司董事长的议案》《关 于变更公司法定代表人的议案》《关于调整公司董事会专门委员会委 员的议案》，现将具体情况公告如下： 一、选举公司董事长的情况 证券代码:300452 证券简称:山河药辅 公告编号：2025-063 债券代码:123199 债券简称:山河转债 安徽山河药用辅料股份有限公司 二、变更公司法定代表人的情况 根据《公司章程》第八条的规定： "董 ...

一、审议通过《关于选举公司董事长的议案》 公司董事会同意选举吴长虹女士为公司第六届董事会董事长，任期 自董事会审议通过之日起至第六届董事会任期届满之日止。 表决结果：同意 8 票，反对 0 票，弃权 0 票。 二、审议通过《关于变更公司法定代表人的议案》 证券代码：300452 证券简称：山河药辅 公告编号：2025-062 债券代码：123199 债券简称：山河转债 安徽山河药用辅料股份有限公司 第六届董事会第九次会议决议公告 本公司及董事会全体成员保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏。 安徽山河药用辅料股份有限公司（以下简称"公司"）第六届董事会 第九次会议于 2025 年 11 月 7 日上午在公司三楼会议室召开，应出席会议 董事8 人，实际出席会议董事 8 人。公司第六届董事会第九次会议通知已 于2025年11月6日以电子邮件、传真及电话通知的方式向全体董事送达， 会议由代理董事长宋道才先生主持。会议的召开符合《中华人民共和国公 司法》和《公司章程》的有关规定。本次会议经审议逐项表决作出如下决 议： 1、第六届董事会第九次会议决议 2、深交所要求的其他文件 特此公告。 安徽山河药 ...